IDEXX Laboratories (IDXX) Q4 2025 Earnings
How Did IDXX Stock React to Q4 2025 Earnings?
Did IDXX Beat Earnings? Q4 2025 Results
Yes. IDEXX Laboratories reported Q4 2025 earnings of $3.08 a share on Feb 2, 2026, beating the $2.94 consensus estimate by 4.8%. Revenue was $1.1B against a $1.1B estimate.
Revenue was $1.09 billion, below the $1.09 billion consensus estimate. EPS was $3.08, above the $2.99 consensus estimate. IDEXX Laboratories reported a 14% increase in revenue for Q4 2025 compared to the same period last year, driven by strong growth in Companion Animal Group (CAG) diagnostics. The company achieved a notable 18% increase in EPS, supported by operating margin expansion and favorable currency impacts. The company projects 2026 revenue to range between $4.63 billion and $4.72 billion, with EPS expected to grow between 9% and 13%. Key growth drivers include the successful launch of IDEXX Cancer Dx for canine lymphoma and the expansion of the IDEXX inVue Dx instrument base.
- Strong CAG Diagnostics recurring revenue growth
- Expansion of IDEXX inVue Dx instrument base
“IDEXX delivered a strong finish to 2025, supported by consistently high levels of execution by IDEXX teams around the world.”
IDEXX Laboratories CEO, on the earnings call
What Was IDEXX Laboratories's Outlook in Q4 2025?
IDEXX Laboratories projects 2026 revenue to range between $4.63 billion and $4.72 billion, reflecting growth of 7.6% to 9.6%. The company expects EPS to increase between 9% and 13%, driven by solid organic revenue gains and operating margin improvements.
IDXX YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $1.1B | $954.3M | +14.3% |
| Gross Profit | $658.1M | $570.6M | +15.3% |
| Operating Income | $315.6M | $261.7M | +20.6% |
| Net Income | $274.6M | $216.1M | +27.1% |
IDXX Revenue by Segment
IDXX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.